Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UroSurge Urinary Incontinence Device To Hit U.S. Market In Next 2 Weeks

This article was originally published in The Gray Sheet

Executive Summary

UroSurge says it will launch the Percutaneous Stoller Afferent Nerve Stimulation (SANS) system in the next two weeks for symptomatic treatment of urinary urgency, frequency or urge incontinence. FDA cleared the device Feb. 9 via a de novo 510(k) with clinical trials as a special control.

You may also be interested in...

Timm Medical Broadens Incontinence Portfolio With UroSurge Acquisition

Timm Medical Technologies plans to proceed with clinical trials of UroSurge's implantable SANS stoller afferent nerve stimulation device for treatment of urinary incontinence if its acquisition of UroSurge closes May 31 as planned. Financial terms of the deal were not disclosed.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts